Neumora Therapeutics NMRA Cash Flow Statement (2022-2026)

NASDAQ NMRA
$0.48 +0.01 (+2.22%)
As of: Oct 21, 2026 · 9:40 AM EDT
Reported Financials

Neumora Therapeutics Quarterly Cash Flow Statement

Periods 16 quarters
Latest Jun 2026

Neumora Therapeutics reported cash from operations of -$39.53M and free cash flow of -$39.53M for the quarter ended Jun 2026, up 24.6% year over year. This cash flow statement covers 16 quarters of results from Sep 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income -29.20M-28.15M-35.63M-38.54M-53.03M-108.73M-53.72M-58.70M-72.55M-58.82M-67.99M-52.73M-56.76M-59.45M-53.46M-43.08M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges 0.30M0.42M0.39M
Depreciation & Amortization (CF)Dep. & Amort. 0.15M0.16M0.17M0.17M0.20M0.16M0.16M0.16M0.16M0.16M0.02M0.02M0.01M0.01M0.01M
Share-based CompensationStock Comp. 2.10M2.79M2.20M2.54M6.45M6.05M7.37M12.77M9.95M9.90M9.32M7.17M5.98M7.41M7.41M7.18M
Gains from Sales and DivestituresGains Divest -0.06M0.07M
Asset Writedowns and ImpairmentWritedown 0.22M
Other non-cash itemsOther Non-Cash 0.02M-0.08M-0.29M-0.18M64.18M-0.36M-1.35M-0.47M-0.23M-0.41M0.00M-0.52M-0.09M0.06M0.06M
Change in Working Capital
Change in Account PayablesChange Payables -3.11M-6.01M7.04M0.31M-1.91M1.16M-0.41M5.03M-2.90M-2.26M-0.41M-0.10M2.83M1.68M-0.91M
Change in Accured ExpensesChange Accured Exp. 7.03M-0.74M3.12M6.26M-2.16M-4.11M1.94M7.58M1.84M1.68M-6.33M4.87M3.98M-4.02M-1.44M
Change in Other Operating AssetsOther Assets Change 2.07M-7.86M4.24M6.89M8.13M-7.35M9.74M-17.69M-0.60M-0.97M-0.15M0.33M3.56M-1.64M1.68M
Change in Other Operating LiabilitiesOther Liabilities Change -0.78M-0.80M-0.82M-0.87M-0.91M-0.80M-0.82M-0.86M-0.89M-0.92M-0.96M0.04M-0.05M-0.07M-0.07M
Other Working Capital ChangesOther WC Changes -6.25M7.06M-5.06M-7.76M-9.04M6.55M-10.56M0.05M-0.81M0.00M1.58M-1.75M
Cash from OperationsCash from Ops. -30.37M-33.04M-31.02M-47.77M-51.44M-42.96M-56.16M-33.48M-50.34M-59.45M-52.40M-46.63M-47.96M-46.40M-39.53M
Investing Activities
Capital ExpendituresCapex 0.02M0.04M0.04M0.04M
Sales of Property, Plant and EquipmentPP&E (Sale) 0.08M0.09M0.05M0.07M
Change in Property, Plant and EquipmentChange in PP&E -0.02M-0.04M-0.04M-0.04M0.08M0.09M0.05M0.07M
Change in IntangiblesChange Intangibless 0.78M
Purchase of InvestmentsInvestments Purchased 48.10M41.48M34.66M12.86M20.07M185.80M19.54M-0.02M106.90M44.39M38.48M
Sale and Maturity of InvestmentsInvestments Sold 40.09M44.34M58.74M36.71M38.38M36.58M40.79M156.97M8.10M88.55M68.80M51.25M42.58M
Cash from Investing ActivitiesCash from Investing -8.03M2.82M24.08M23.82M13.68M-150.00M21.26M156.99M-98.80M44.16M30.40M51.32M42.65M0.07M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance -0.14M38.90M
Non-Current Debt -0.14M38.90M
Net Debt Issuances and RepaymentsNet Debt Issuance -0.14M38.90M
Change in Capital Stock
Common Stock IssuedStock Issued 1.66M0.60M0.40M234.89M0.34M1.85M2.65M1.76M1.65M0.06M0.22M
Net Shares Issued and RepurchasedNet Shares Issued 1.66M0.60M0.40M234.89M0.34M1.85M2.65M1.76M1.65M0.06M0.22M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued 24.97M
Net Equity Issued and RepurchasedNet Equity Issued 26.63M0.60M0.40M234.89M0.34M1.85M2.65M1.76M1.65M0.06M0.22M
Other financing activitiesOther financing 0.21M-0.50M-0.11M-2.86M-0.82M
Cash from Financing ActivitiesCash from Financing 26.83M0.10M0.29M232.02M-0.48M1.85M2.65M1.53M15.57M18.46M-0.14M58.77M10.88M9.29M
Additional items
Change in Cash -11.56M-30.12M-6.65M208.07M-38.25M-191.11M-32.25M125.04M-133.57M-15.29M-3.55M4.55M53.46M-35.46M-30.24M
Ending Cash Balance 253.77M242.21M212.08M205.43M413.50M375.25M184.14M151.89M276.93M143.36M128.07M124.52M129.07M182.53M147.07M116.83M
Free Cash FlowFCF -30.39M-33.08M-31.02M-47.81M-51.49M-42.96M-56.16M-33.48M-50.34M-59.45M-52.40M-46.63M-47.96M-46.40M-39.53M
Net Cash FlowNCF -11.56M-30.12M-6.65M208.07M-38.25M-191.11M-32.25M125.04M-133.57M-15.29M-3.55M4.55M53.46M-35.46M-30.24M
Interest Paid 0.13M0.53M0.83M1.46M
Income Taxes PaidTaxes Paid 0.47M0.32M0.03M

Neumora Therapeutics Cash Flow Statement API

Pull Neumora Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=NMRA&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY